Cardiac arrhythmias reported during treatment with cisapride

Tooley, P. J. H.; Vervaet, P.; Wager, Elizabeth

doi:10.1002/(sici)1099-1557(199901/02)8:1<57::aid-pds391>3.3.co;2-x

Cited by 4 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cisapride has activity at the hERG encoded Ikr channel, a potassium ion channel that is responsible for the repolarizing I Kr current in the cardiac action potential 14–16 . Cisapride treatment has been associated with rare cardiovascular side effects, notably in those patients with predisposing conditions, such as cardiac disease or those taking concomitant medications that might inhibit the metabolism of cisapride through the cytochrome P450 CYP3A4 pathways 17,18 . Ischaemic cardiac effects have been reported with tegaserod; whether this finding is associated with the use of the drug or occurs spontaneously in an at‐risk population is less clear 19–22 …”

Section: Introductionmentioning

confidence: 99%

Safety assessment of prucalopride in elderly patients with constipation: a double‐blind, placebo‐controlled study

Camilleri

Beyens

Kerstens

et al. 2009

Neurogastroenterology Motil

119

View full text Add to dashboard Cite

Chronic constipation is common among nursing home residents. The aim of this study was to evaluate safety, tolerability and pharmacokinetics of the selective 5HT 4 receptor agonist prucalopride in elderly, chronically constipated patients in nursing homes. A multicentre, phase II, randomized, doubleblind dose-escalation study in 89 elderly constipated nursing home residents treated with placebo, 0.5, 1 or 2 mg prucalopride once daily for 28 days was analysed. Adverse events, vital signs, ECG, Holter monitor and pharmacokinetics were assessed (Clinicaltrials.gov identifier: NCT00627692). PatientsÕ mean age was 83 years; 88% had a history of cardiovascular diseases. Most frequent adverse events, at least possibly related to prucalopride, were diarrhoea and abdominal pain. Relative to placebo, there were no differences in vital signs, ECG corrected QT interval, ECG morphology parameters, or incidence of supraventricular or ventricular arrhythmias on Holter monitoring. Plasma prucalopride concentrations increased proportionally with administered dose. Prucalopride up to 2 mg once daily for 4 weeks was safe and well-tolerated by constipated elderly patients, with no differences vs placebo in ECG or a range of Holter-monitoring parameters.

show abstract

Section: Introductionmentioning

confidence: 99%

Safety assessment of prucalopride in elderly patients with constipation: a double‐blind, placebo‐controlled study

Camilleri

Beyens

Kerstens

et al. 2009

Neurogastroenterology Motil

119

View full text Add to dashboard Cite

show abstract

“…Myoclonus is infrequent in SCA2 and usually present in late disease stages, whereas it is a typical clinical feature of other dominant ataxias such as DRPLA, SCA14, and SCA19. 2 Piracetam (2-oxo-1-pyrrolidine-acetamide) at high doses is an effective and well-tolerated drug for treatment of myoclonus. 3 …”

Section: Introductionmentioning

confidence: 99%

“…1 The use of cisapride has been discontinued by the U.S. Food and Drug Administration (FDA) due to the risk of fatal arrhythmia. 2 One recent study found that mosapride, a 5-HT4 agonist, effectively reduces constipation in parkinsonian patients. 3 We performed a double-blind randomized placebo-controlled pilot study to determine whether another prokinetic medication, tegaserod (Zelnorm), improved constipation in 15 patients with PD.…”

mentioning

confidence: 99%

Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease

et al. 2005

View full text Add to dashboard Cite

We performed a double-blind randomized placebo-controlled pilot study to determine the efficacy of tegaserod (Zelnorm) in treating constipation in 15 patients with Parkinson's disease (PD). There was a trend for improvement in the Subject's Global Assessment (SGA) of satisfaction with bowel habits (NS) and the total SGA (including abdominal discomfort, bothersome constipation, and satisfaction; NS).

show abstract

“…Cisapride has been withdrawn from the market in several European countries because of its association with cardiac arrhythmias and death [184].…”

Section: Gastrointestinal Motility Problemsmentioning

confidence: 99%

Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease

Horstink

Tolosa

Bonuccelli

et al. 2006

Euro J of Neurology

166

107

View full text Add to dashboard Cite

To provide evidence-based recommendations for the management of late (complicated) Parkinson's disease (PD), based on a review of the literature. Complicated PD refers to patients suffering from the classical motor syndrome of PD along with other motor or non-motor complications, either disease-related (e.g. freezing) or treatment-related (e.g. dyskinesias or hallucinations). MEDLINE, Cochrane Library and INAHTA database literature searches were conducted. National guidelines were requested from all EFNS societies. Non-European guidelines were searched for using MEDLINE. Part II of the guidelines deals with treatment of motor and neuropsychiatric complications and autonomic disturbances. For each topic, a list of therapeutic interventions is provided, including classification of evidence. Following this, recommendations for management are given, alongside ratings of efficacy. Classifications of evidence and ratings of efficacy are made according to EFNS guidance. In cases where there is insufficient scientific evidence, a consensus statement (Ôgood practice pointÕ) is made.

show abstract

Cardiac arrhythmias reported during treatment with cisapride

Cited by 4 publications

References 0 publications

Safety assessment of prucalopride in elderly patients with constipation: a double‐blind, placebo‐controlled study

Safety assessment of prucalopride in elderly patients with constipation: a double‐blind, placebo‐controlled study

Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease

Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease

Contact Info

Product

Resources

About